Human papillomavirus 9-valent vaccine, recombinant - Biologic Drug Details

Summary for human papillomavirus 9-valent vaccine, recombinant

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for human papillomavirus 9-valent vaccine, recombinant

Recent Clinical Trials for human papillomavirus 9-valent vaccine, recombinant

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Merck Sharp & Dohme Corp.	Early Phase 1
Boston Medical Center	Early Phase 1
Merck Sharp & Dohme Corp.	Phase 3

See all human papillomavirus 9-valent vaccine, recombinant clinical trials

Pharmacology for human papillomavirus 9-valent vaccine, recombinant

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Human Papillomavirus Vaccine
Chemical Structure	Papillomavirus Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for human papillomavirus 9-valent vaccine, recombinant Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for human papillomavirus 9-valent vaccine, recombinant Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508		2038-12-04	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508		2041-02-09	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508		2026-01-13	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508		2027-05-23	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508		2023-07-28	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for human papillomavirus 9-valent vaccine, recombinant Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508		2036-07-21	Patent claims search

International Patents for human papillomavirus 9-valent vaccine, recombinant

Country	Patent Number	Estimated Expiration
Dominican Republic	P2022000168
Costa Rica	20220395
Japan	2007507207
European Patent Office	1298211
Luxembourg	91387

Supplementary Protection Certificates for human papillomavirus 9-valent vaccine, recombinant

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0790016-0	Sweden		PRODUCT NAME: VIRUA RESEMBLING NDE OF L1 PROTEIN OF HPV18; REGISTRATION NO/DATE: EU/1/06/357 and EU/1/06/358 20060920
76/2007	Austria		PRODUCT NAME: KOMBINATION VON HPV16 + HPV18 VIRUSARTIGEN PARTIKELN; REGISTRATION NO/DATE: EU/1/07/419/001-009 20070920
00169	Estonia		PRODUCT NAME: HPV 45 L1 VALK; NATIONAL AUTHORISATION NUMBER: EMA/PDCO/731437/2013 17.01.2014
75/2007	Austria		PRODUCT NAME: HPV16 VIRUSARTIGE PARTIKEL; REGISTRATION NO/DATE: EU/1/07/419/001 - 009 20070920
C201530072	Spain		PRODUCT NAME: PROTEINA L1 VPH 45; NATIONAL AUTHORISATION NUMBER: EU/1/15/1007; DATE OF AUTHORISATION: 20150610; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1007; DATE OF FIRST AUTHORISATION IN EEA: 20150610

Market Dynamics and Financial Trajectory for the Human Papillomavirus 9-Valent Vaccine, Recombinant

Last updated: August 16, 2025

Introduction

The human papillomavirus (HPV) 9-valent recombinant vaccine (commercially known as Gardasil 9) represents a significant advancement in prophylactic immunization against HPV-related diseases. Since its approval, it has transformed public health strategies worldwide, aiming to reduce the incidence of cervical and other HPV-associated cancers. This analysis explores the evolving market dynamics, financial trajectory, and future outlook of Gardasil 9, considering factors such as demographic trends, competitive landscape, regulatory developments, and emerging innovations.

---

Market Overview

Global Burden of HPV-Related Diseases

HPV is the most common sexually transmitted infection globally, with an estimated 80% of sexually active individuals contracting at least one HPV type during their lifetime [1]. Persistent infection with high-risk HPV genotypes can lead to cervical, anal, oropharyngeal, and other anogenital cancers. Cervical cancer remains the fourth most common cancer among women worldwide, with an estimated 600,000 new cases annually [2].

Vaccination as a Preventative Strategy

The introduction of HPV vaccines has dramatically reduced the incidence of high-risk HPV infections and associated precancerous lesions. The 9-valent vaccine, covering HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, broadens protection against approximately 90% of cervical cancers attributable to HPV [3].

---

Market Dynamics

Growth Factors

Expanding Global Adoption

The expanding inclusion of HPV vaccination in national immunization programs (NIPs) underpins market growth. Over 100 countries incorporate HPV vaccines into their NIPs, with coverage increasing notably in high-income and upper-middle-income nations [4].

Demographic Trends

The target demographic, primarily adolescents aged 9-14, signifies a substantial and growing market segment, especially as global vaccination initiatives extend into low- and middle-income countries (LMICs). The World Health Organization (WHO) aims for 90% of girls to be vaccinated by 15 years of age by 2030, enhancing future demand [5].

Awareness and Education Campaigns

Increased awareness and educational campaigns have improved vaccine acceptance, especially amid global efforts to eliminate cervical cancer. Advocacy efforts by WHO, CDC, and various health authorities influence market penetration rates.

Competitive Landscape

Established Leaders

Merck & Co. (marketed as Gardasil 9) dominates the HPV vaccine space, supplemented by Cervarix (GSK) and HPV9 (Indian pharmaceutical companies). Gardasil 9’s broad coverage and extensive clinical data give it a competitive edge.

Emerging Innovation and Biosimilars

While no biosimilars currently threaten Gardasil 9's market share, the pipeline includes next-generation vaccines focusing on broader antigen coverage, thermostability, and single-dose regimens, potentially disrupting existing dynamics [6].

Regulatory Environment

WHO prequalification, approval by U.S. FDA, EMA, and other agencies facilitate market access. Ongoing regulatory approvals extend geographic reach, especially in LMICs, where Gavi, the Vaccine Alliance, supports procurement.

Pricing and Reimbursement

Pricing strategies vary globally. High-income markets enjoy premium pricing facilitated by reimbursement schemes, whereas LMICs benefit from tiered pricing and Gavi support. Price sensitivity influences uptake rates and market expansion.

---

Financial Trajectory

Revenue Projections

Forecasts project that the HPV vaccine market, valued at approximately USD 4.9 billion in 2022, will grow at a compound annual growth rate (CAGR) of 8-10% through 2030, driven by increased coverage and population growth (notably in Africa and Southeast Asia) [7].

Market Penetration and Sales Volumes

In high-income countries such as the US, Europe, and Japan, vaccination rates are stabilizing at high levels, bolstering sustained revenues. In LMICs, rising vaccination coverage is expected to generate exponential growth in sales volumes.

Pricing Trends and Profitability

While initial prices for Gardasil 9 were around USD 150-200 per dose in developed markets, negotiations and Gavi support have reduced costs in LMICs. The introduction of flexible dosing schedules (e.g., two-dose regimens) could further lower costs and expand accessibility, positively impacting profitability.

Impact of Patent Expiry and Biosimilar Entry

Currently, no biosimilar vaccines are marketed, safeguarding Merck’s market share. However, patent protection expiry debates and technological advances in vaccine manufacturing could open avenues for generics, influencing future revenue streams.

---

Future Outlook and Market Drivers

Technological Innovations

Next-generation vaccines with thermostability, single-dose schedules, or broader antigenic coverage aim to simplify immunization protocols, reduce costs, and improve adherence.

Global Health Initiatives

WHO’s goal for cervical cancer elimination underscores increasing government funding and international aid, particularly in LMICs. Such initiatives will perpetuate demand for Gardasil 9.

Novel Vaccination Strategies

Exploration of therapeutic HPV vaccines and mucosal delivery methods could complement prophylactic approaches, expanding the therapeutic landscape.

Challenges

Vaccine hesitancy, particularly in regions with cultural resistance, remains a critical challenge. Addressing misinformation is vital to maintaining growth trajectories.

---

Conclusion

The human papillomavirus 9-valent recombinant vaccine stands at the nexus of public health and biopharmaceutical innovation. Its market is driven by global efforts to reduce HPV-related cancers, demographic shifts, strategic government initiatives, and technological advancements. While high-income markets currently dominate revenue streams, burgeoning demand in LMICs promises significant future growth. The financial trajectory hinges on addressing affordability, vaccine acceptance, and competitive developments. Overall, Gardasil 9’s market outlook remains optimistic, with sustained growth anticipated through strategic expansion, technological innovation, and integrated public health policies.

---

Key Takeaways

• Market Growth is Robust: Driven by expanding vaccination programs and increasing awareness, the HPV vaccine market is projected to grow at an 8-10% CAGR through 2030.
• High-Income Markets Stabilize: Established markets are mature with high coverage, contributing consistent revenue streams.
• Emerging Markets Offer Significant Opportunities: LMICs represent a high-growth segment, supported by Gavi and international health initiatives.
• Innovation Is Key: Next-generation vaccines and dosing schedules will shape future dynamics, potentially reducing costs and increasing global access.
• Regulatory and Strategic Collaborations Are Crucial: Approvals and partnerships facilitate market expansion, especially in underserved regions.

---

FAQs

1. How does Gardasil 9 differ from earlier HPV vaccines?
Gardasil 9 covers nine HPV types, including additional high-risk genotypes (like 31, 33, 45, 52, 58), offering broader protection compared to earlier vaccines such as Gardasil 4, which covered four types. This comprehensive coverage aims to prevent approximately 90% of HPV-related cancers.

2. What factors influence the pricing of Gardasil 9 in different markets?
Pricing varies based on market income level, negotiation power of governments, Gavi support in LMICs, and regulatory policies. High-income countries typically pay higher prices, while tiered pricing and subsidies lower costs in LMICs.

3. What is the current status of vaccine accessibility in low-income countries?
Gavi and WHO support efforts to improve access in LMICs through funding and procurement assistance. However, challenges such as vaccine hesitancy and logistical hurdles still impact coverage rates.

4. Are there emerging competitors or biosimilars in the HPV vaccine space?
No biosimilars are currently marketed for Gardasil 9. However, technological innovations and patent expirations may introduce competitors in the future, potentially impacting market share.

5. What are the future innovations expected in HPV vaccination?
Research focuses on thermostable vaccines, single-dose regimens to enhance compliance, and therapeutic vaccines to treat existing infections, which could further transform the market landscape.

---

References

[1] WHO. Human papillomavirus (HPV) and cervical cancer. 2021.

[2] GLOBOCAN 2020. Cervical Cancer Fact Sheet. IARC.

[3] Centers for Disease Control and Prevention (CDC). HPV Vaccine Recommendations. 2022.

[4] Gavi, the Vaccine Alliance. HPV vaccine market data. 2022.

[5] WHO. Global Strategy to Accelerate the Elimination of Cervical Cancer. 2020.

[6] Market Research Future. HPV Vaccine Market Reports. 2022.

[7] Research and Markets. Global HPV Vaccines Market Forecasts. 2022.